Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis
Brief Summary: To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.


Options:
A: Arm Label: Cladribine 5.25 mg/kg (ITP); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Cladribine 3.5 mg/kg (ITP); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Placebo (ITP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Rebif® new formulation (RNF) | Arm Label: Cladribine 5.25 mg/kg, Rebif (OLMP); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Cladribine 3.5 mg/kg, Rebif (OLMP); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Placebo, Rebif (OLMP); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cladribine 5.25 mg/kg, Rebif (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Cladribine 3.5 mg/kg, Rebif (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Cladribine, Drug: Rebif® new formulation (RNF) | Arm Label: Placebo, Rebif (LTFU); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine 3.5 mg/kg (ITP), Cladribine 3.5 mg/kg, Rebif (LTFU), Cladribine 3.5 mg/kg, Rebif (OLMP), Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU), Cladribine 5.25 mg/kg (ITP), Cladribine 5.25 mg/kg, Rebif (LTFU), Cladribine 5.25 mg/kg, Rebif (OLMP), Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (ITP), Placebo, Rebif (LTFU), Placebo, Rebif (OLMP), Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU) | Intervention Type: DRUG; Name: Rebif® new formulation (RNF); Assigned to Arm(s): Cladribine 3.5 mg/kg (ITP), Cladribine 3.5 mg/kg, Rebif (LTFU), Cladribine 3.5 mg/kg, Rebif (OLMP), Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU), Cladribine 5.25 mg/kg (ITP), Cladribine 5.25 mg/kg, Rebif (LTFU), Cladribine 5.25 mg/kg, Rebif (OLMP), Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU), Placebo (ITP)
B: Arm Label: Several diagnostic procedures; Type: OTHER; Interventions: Procedure: Several diagnostic procedures | Intervention Type: PROCEDURE; Name: Several diagnostic procedures; Assigned to Arm(s): Several diagnostic procedures
C: Arm Label: Group 1; Type: N/A; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): Group 1
D: Arm Label: RNF 44 mcg three times weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo twice weekly for blinding; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo three times weekly; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo three times weekly, RNF 44 mcg once weekly and placebo twice weekly for blinding

Answer: C